Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • AIIMS releases...

    AIIMS releases guidance on Antibiotics in Osteomyelitis

    Written by Dr. Kamal Kant Kohli Kohli Published On 2020-01-02T19:00:36+05:30  |  Updated On 2 Jan 2020 7:00 PM IST
    AIIMS releases guidance on Antibiotics in Osteomyelitis
    All India Institute of Medical Sciences, Delhi has released AIIMS Antibiotics Policy which has been prepared by the Department of Medicine with Multidisciplinary collaboration. The guidance for antibiotics in orthopaedics Infections includes Osteomyelitis the salient features of which are hereunder.

    Acute Osteomyelitis (<6 weeks)


    When to suspect





    • Pain, swelling, redness of the involved site

    • Tenderness, painful movement of joints

    • Young children may present with fever, irritability and lethargy along with local symptoms



    How to confirm




    • Complete blood count (CBC) with differential count, Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)

    • Blood culture

    • Pus culture - Aspirate pus from deep tissues. Swab is not representative specimens. Send for gram stain, KOH mount, Ziehl Neelsen (ZN) staining and geneXpert. Send cultures for bacterial/fungal/tubercular (MGIT) (as deemed necessary)

    • Plain radiograph

    • Investigation of choice is Magnetic resonance imaging (MRI). If MRI cannot be done- Positron emission tomography (PET) /Bone scintigraphy


    Chronic osteomyelitis (>6 weeks)


    When to suspect




    • Chronic pain, erythema and swelling

    • Presence of sinus tract with pus discharge


    How to confirm




    • Investigation of choice- Plain radiograph/ MRI (if MRI cannot be done- Bone scintigraphy)

    • CBC with differential count, ESR, CRP

    • Pus culture (Caution should be exercised while interpreting Pus culture reports from the sinus of chronic osteomyelitis due to high probability of contamination from skin flora). Send for gram stain, KOH mount, ZN and geneXpert. Send cultures for bacterial/fungal/tubercular.

    • Bone biopsy culture- at least three bony samples (stop antibiotics two weeks before)


    Surgical treatment of Osteomyelitis:


    Acute: Surgical debridement –in acute osteomyelitis is preferred if there is definitive evidence of pus collection in sub-periosteal/ intramuscular plane (demonstrated by either USG or MRI)


    Chronic: Surgical debridement with sequestrectomy is the treatment of choice- Antibiotic loaded cement spacers may be added during surgery


    Medical treatment of Osteomyelitis:


    a) Empiric- No risk factors for multi-drug resistance (MDR)- MSSA, Group A Streptococcus


    Preferred: IV- Cefazolin 2g TDS (2) or Ceftriaxone 2g IV OD


    Oral- Linezolid 600 mg BD plus/minus Rifampicin (600 mg OD)


    Alternative: IV- Cefuroxime 1.5 g TDS can be used instead of Cefazolin /Ceftriaxone


    Special remarks:


    Oral therapy recommended only after initial stabilization with IV therapy in bacterial osteomyelitis


    Fluoroquinolones and linezolid achieve bone concentrations at ∼50% of serum


    Oral beta-lactams not recommended for the treatment of osteomyelitis. Rifampicin has to be always used in combination


    The minimum duration of treatment is 6 weeks for bacterial osteomyelitis


    Vancomycin not recommended for MSSA- high rate of recurrence


    b) Empiric - Risk factors for MDR- MRSA, GNB


    Preferred: IV- Vancomycin 1-2g IV BD or Teicoplanin 400 mg IV OD Plus Piperacillin-tazobactam 4.5 g QID or Cefoperazone sulbactam 2-3 g IV BD


    Oral- Linezolid plus/minus Rifampicin Plus Ciprofloxacin 750 mg BD


    Alternative: Daptomycin 6mg/kg OD can be used instead of vancomycin/ teicoplanin.


    Imipenem 500 mg QID Or Meropenem 1g TDS can be used instead of Piperacillin tazobactam/ Cefoperazone sulbactam


    Special remarks:


    -Risk factors for MDR- recent hospitalization, recent surgery/ trauma, HIV, prior antibiotic use, IDU and diabetic


    -Monitor CPK levels in a patient receiving daptomycin


    c) Tuberculosis:


    According to RNTCP/INDEX-TB guidelines (9)- 2 months of intensive phase with HRZE followed by 10-16 months continuation phase of HRE


    d) Non-tubercular mycobacteria (Rapid growers):


    Combination chemotherapy with an oral agent (choose from Cotrimoxazole, ciprofloxacin and doxycycline) and two intravenous agents (amikacin, imipenem) for 4-6 weeks – followed by three oral agents (choose from clarithromycin, Cotrimoxazole, ciprofloxacin, doxycycline, linezolid, rifabutin)


    e) Candida:


    Preferred:




    • Anidulafungin 200 mg loading followed by 100 mg IV OD for 2 weeks at-least.

    • Micafungin (100 mg OD) or Caspofungin (70 mg followed by 50 mg OD) can also be used.

    • Maybe de-escalated to Fluconazole therapy (400 mg daily) based on sensitivity for another 4-6 weeks


    Alternative:


    Liposomal Amphotericin (3-5mg/kg) OD for 2 weeks followed by oral Fluconazole therapy


    f) Aspergillus:




    • Preferred: Voriconazole 6mg/kg two doses 12hrs apart (loading) followed by 4mg/kg BD (iv or oral) for a minimum of 8 weeks

    • Alternative: Amphotericin (3-5mg/kg/day) OD for a minimum of 8 weeks

    • Special Remarks:Suspect in Post-trauma/ surgical intervention or co-existing pulmonary disease.Therapeutic drug monitoring with voriconazole should be done (Normal range 1-5µg/ml).


    g) Mucormycosis:




    • Injection liposomal Amphotericin B (at least 5 mg/kg/day)

    • After initial stabilization with IV therapy for at least 8 weeks- can be shifted to oral suspension Posaconazole (200mg QID)


    Special Remarks:


    - When shifting from amphotericin B to posaconazole, one week of overlap may be beneficial.


    - Posaconazole should be administered with fatty food and cola beverages.


    -TDM for Posaconazole should be done if available.


    Chronic osteomyelitis:


    Choice of empirical antibiotics is similar to acute osteomyelitis. Definitive antibiotics to be guided by culture results- Total antibiotic duration- a minimum of 6 weeks.

    AIIMSAll India Institute of Medical Sciencesantibioticsosteomyelitis
    Source : All India Institute of Medical Sciences

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok